🎁
DIWALI SPECIAL

20% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
INNOVA CAPTAB

INNOVA CAPTAB Latest Share Price (INNOVACAP)

NSE: INNOVACAPBSE 544067HealthcarePharmaceuticalsinnovacaptab.com
₹1,044.70
6.40−0.61%
Overall Score52/100
Day range1,045
₹1,044.70
1,052
52-week622
₹1,044.70
1,354
Above low+68.0%
Below high22.8%
Range position58%
Open1,049.40
Prev Close1,051.10
Bid1,044.65100
Ask1,044.75100

TODAY IN ONE LINE

INNOVACAP slipped 0.6% on light volume, in line with Nifty's 0.1% move.

With a market cap of ₹5,980.01 Cr., it trades at a P/E of 38.26. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume24−100%vs 20D avg
Price Band20
Lower Band797.2
Upper Band1,195.8
Tick Size0.10
Daily Volatility2.33%
Annualised Vol44.51%
Market Cap₹5,980.01 Cr.
Promoter50.9%
Face Value₹10
Fwd P/E20.96
PEG1.43
EV/EBITDA21.07
P/S3.44
ROA6.83%
Beta0.76
Div Payout8.11%
THE STOCK SCORE
Overall Score52/100
Updated 30 Oct

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

INNOVA CAPTAB flags & news 

Key strengths, potential risks, and recent updates.

✅ 2 green flags🚩 2 red flags

Green Flags

  • ●Earnings GrowthEPS (TTM) grew by a solid 28.6% YoY
  • ●High Promoter HoldingPromoters hold 50.9% skin-in-the-game

Red Flags

  • ●Rising Receivables vs SalesReceivables grew 20.7% outpacing sales growth of 15.0%
  • ●Promoter Pledging DetectedPledge activity recorded on 30-Sep-2025 14:08

Latest INNOVA CAPTAB News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

INNOVA CAPTAB valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for INNOVA CAPTAB, framed against the sector median so the premium or discount is obvious at a glance.

INNOVA CAPTAB trades at a P/E of 38.26× and P/B of 5.53×.

Key MetricsMarket + reported · 30 Oct 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹5,980.01 Cr.
P/E Ratio
38.26
P/B Ratio
5.53
EPS
₹26.91
Profitability

Profitability

ROE
12.92%
ROCE
10.77%
Net Margin
8.65%
Op Margin
12.59%
Growth

Growth

EPS YoY
28.6%
Revenue YoY
42.3%
Qtr Sales
—
Qtr Profit
—
Financial Health

Financial Health

Debt / Equity
0.32
Book Value
₹190.62
Div Yield
0.38%
Promoter Holding
50.9%
Technicals

INNOVA CAPTAB technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INNOVA CAPTAB — derived from the latest tape, not yesterday's close.

INNOVA CAPTAB last traded at ₹1,044.7 with an intraday range of ₹1,044.7–₹1,051.9 — latest indicator, pivot and CPR signals below.

Last updated: 30 October 2026, 9:17 am IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹1044.70
LevelPrice (₹)Distance% Δ
R41063.90+19.20+1.84%
R31056.70+12.00+1.15%
R21054.30+9.60+0.92%
R11049.50+4.80+0.46%
PIVOT1047.102.400.23%
CURRENT1044.70——
S11042.30-2.40-0.23%
S21039.90-4.80-0.46%
S31035.10-9.60-0.92%
S41027.90-16.80-1.61%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 1045.90P: 1047.10TC: 1048.30
R1
R2
R3
R4
indicator
LTP: 1044.70
PDH: 1093.90
PDL: 1041.00
● Market Sentiment

INNOVACAP is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Average

● Opening Range

Day's range: ₹–₹

● Price Position

Trading Inside opening range

Financials

INNOVA CAPTAB financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for INNOVA CAPTAB — consolidated or standalone — with margins, YoY growth and key ratios inline.

INNOVA CAPTAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,980.01 Cr. and reported EPS of ₹26.91.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026May 2026
Revenue from Operations1,630
1,630
▲ 0.0%
Sales Growth YoY %Derived31.06%
31.06%
Other Income7
7
▲ 0.0%
Total Income1,637
1,637
▲ 0.0%
1,053
1,053
▲ 0.0%
Gross ProfitDerived577
577
▲ 0.0%
Gross Margin %Derived35.41%
35.41%
334
334
▲ 0.0%
EBITDA (Operating Profit)Derived243
243
▲ 0.0%
OPM %Derived14.90%
14.90%
62
62
▲ 0.0%
Profit Before Tax (PBT)188
188
▲ 0.0%
45
45
▲ 0.0%
Effective Tax %Derived23.95%
23.95%
Total Profit for Period143
143
▲ 0.0%
Net Profit (Owner's PAT)Derived143
143
▲ 0.0%
Net Profit Margin %Derived8.78%
8.78%
PAT Growth YoY %Derived11.64%
11.64%
Earnings Per Share (EPS ₹)25.02
25.02
▲ 0.0%
Diluted Shares Outstanding (Cr)6
6
▲ 0.0%
Other Comprehensive Income (Net of Tax)0
0
▲ 0.0%
Total Expenses (incl. D&A & Interest)1,449
1,449
▲ 0.0%
Material Cost % of RevenueDerived61.68%
61.68%
Employee Cost % of RevenueDerived10.26%
10.26%
Other Cost % of RevenueDerived10.25%
10.25%
Interest Coverage (x)Derived11.70x
11.70x
Sales CAGR · 3Y
+9.4%
Sales CAGR · 5Y
+8.6%
PAT CAGR · 3Y
+3.7%
PAT CAGR · 5Y
+8.7%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

INNOVA CAPTAB segment analysis : revenue and profit mix.

Disclosed business segments at INNOVA CAPTAB with their share of revenue and profit, switchable between consolidated and standalone reporting.

INNOVA CAPTAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for INNOVA CAPTAB.

Our AI distills the core fundamental drivers supporting INNOVA CAPTAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 50 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

Shareholding

INNOVA CAPTAB shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in INNOVA CAPTAB — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Promoters50.90%
Public29.09%↑0.25%
DII19.16%↓0.76%
FII0.84%↑0.50%

Ownership Distribution

Promoters
50.90%
Retail & Public
29.09%
Domestic Institutions
19.16%
Foreign Institutions
0.84%

Category Trends

Foreign Institutions Breakdown
Total Holding: 0.84%
Net Change: +0.50%
Category Total0.84%
Total Holding0.84%
Net Change+0.50%
Aggregate Data
Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod

Foreign Institutions: 0.84%

Individual institutional breakdown is not disclosed by the company, but aggregate holding data is shown above.

💡 This category has 0.84% total holding without detailed institution-wise disclosure
Peers

INNOVA CAPTAB peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INNOVA CAPTAB is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
SUN PHARMACEUTICAL IND L
₹4.23 Lakh Cr
Best Profit Growth
ONESOURCE SPECL PHARMA L
443.77 %
Highest Dividend Yield
SANOFI INDIA
3.86 %

Peer Comparison

Company Name
09 · Chart Patterns

INNOVA CAPTAB chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for INNOVA CAPTAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

INNOVA CAPTAB delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for INNOVA CAPTAB over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in INNOVA CAPTAB stood at 43.8% of traded volume, against a 20-day average of 47.1%.

Avg Delivery (20D)47.1%-3.4 ppt latest vs avg
Highest Delivery56.8%on 12 Oct
Avg Volume (20D)98.9 K20-day run-rate
Conviction Trend↓ Weakening-3.4 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

INNOVA CAPTAB announcements: results, concalls, ratings, M&A.

Filings INNOVA CAPTAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

INNOVA CAPTAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 126 documents below.

  1. 07 Oct 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018View PDF

    Certificate under SEBI (Depositories and Participants) Regulations, 2018

    Innova Captab Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  2. 02 Oct 2026Shareholders meetingView PDF

    Shareholders meeting

    Innova Captab Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the…

  3. 30 Sept 2026Shareholders meetingView PDF

    Shareholders meeting

    Innova Captab Limited has informed the Exchange about Shareholders meeting

  4. 29 Sept 2026Credit Rating- RevisionView PDF

    Credit Rating- Revision

    Innova Captab Limited has informed the Exchange about Credit Rating- Revision

  5. 28 Sept 2026Trading WindowView PDF

    Trading Window

    Innova Captab Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…

Corporate Actions

INNOVA CAPTAB dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue INNOVA CAPTAB has declared, sequenced by announce and record date.

INNOVA CAPTAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

INNOVA CAPTAB insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in INNOVA CAPTAB as reported to SEBI — buying and selling signals from the people who know the business best.

INNOVA CAPTAB insider activity below tracks 5 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Archit AggarwalInsider24 Mar 2026buy+43.75 L₹302.31 Cr.₹691.00
Archit AggarwalInsider24 Mar 2026buy+43.75 L₹302.31 Cr.₹691.00
Archit AggarwalInsider24 Mar 2026buy+43.75 L₹302.31 Cr.₹691.00
Archit AggarwalInsider24 Mar 2026buy+43.75 L₹302.31 Cr.₹691.00
Archit AggarwalInsider24 Mar 2026buy+43.75 L₹302.31 Cr.₹691.00
About the Company

About INNOVA CAPTAB: business, sector, key facts.

What INNOVA CAPTAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

INNOVA CAPTAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: INNOVACAP, BSE: 544067.

INNOVACAP
Healthcare

INNOVA CAPTAB

NSE · INNOVACAP·BSE · 544067·innovacaptab.com

Innova Captab Limited is an integrated pharmaceutical company operating in India and internationally. Its core business encompasses the entire pharmaceutical value chain, from research and development to marketing and distribution of its own products and those of other companies. This vertical integration allows for greater control over quality and efficiency throughout the process.

A significant portion of Innova Captab's business involves contract development and manufacturing organization (CDMO) services. The company provides these services to other Indian pharmaceutical firms, leveraging its manufacturing capabilities and expertise to produce drugs according to their specifications. This aspect of the business generates revenue streams independent of the company's own branded products.

Innova Captab manufactures and distributes a wide range of generic formulation products covering numerous therapeutic areas. These include but are not limited to antibiotics (cephalosporins, fluoroquinolones, macrolides), cardiovascular drugs, analgesics, anti-inflammatory agents, antidiabetic medications, and treatments for various other conditions. The company produces these drugs in diverse forms, including tablets, capsules, syrups, injections, and ointments, showcasing its versatility in pharmaceutical manufacturing.

The company's branded generic products reach the market through a multi-channel distribution strategy. This includes a traditional network of distributors and pharmacies, as well as a growing online presence via e-commerce pharmacy websites. This diversified approach allows Innova Captab to access a broader customer base and enhance market reach.

In summary, Innova Captab Limited operates a multifaceted pharmaceutical business model. It combines CDMO services for other pharmaceutical companies with the development, manufacture, and distribution of its own portfolio of branded generic drugs, achieving market access via both traditional and online channels. This integrated approach positions the company strategically within the competitive Indian and international pharmaceutical markets.

company facts
Employees—
SectorHealthcare
HeadquartersPanchkula, India
Market Cap₹5,980.01 Cr.
Listed OnNSE
leadership22 on record
Anup Agarwal
Director
Mahendar Korthiwada
Director
Mr. Archit Aggarwal
Director
Mr. Ayush Kumar Garg
Head of Investor Relations
Mr. Gian Aggarwal
Director
Mr. Jayant Rao
Whole-Time Director
Mr. Jayant Vasudeo Rao
Whole-time Director
Mr. Lokesh Bhasin
Chief Financial Officer
Mr. Lokesh Bhasin
Chief Financial Officer
Mr. Manoj Kumar Lohariwala
Executive Chairman
Mr. Manoj Lohariwala
Whole-Time Director
Mr. MukeshKumar Siyaram Singh
Deputy Chief Financial Officer
§ ∞ · Plainly Answered

Questions investors ask about INNOVA CAPTAB (INNOVACAP).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of INNOVA CAPTAB (INNOVACAP)?

The current share price of INNOVA CAPTAB (INNOVACAP) is ₹1,044.70. Today, the stock has declined by ₹6.40 (0.61%), trading in a range of ₹1,044.70 to ₹1,051.90. The stock opened at ₹1,049.40 with a trading volume of 24 shares.

02Is INNOVA CAPTAB stock a good investment for long-term?

INNOVA CAPTAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,980.01 Cr., P/E ratio of 38.26, ROE of 12.92%, and ROCE of 10.77%. The dividend yield stands at 0.38%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of INNOVA CAPTAB stock?

The 52-week high price of INNOVA CAPTAB (INNOVACAP) is ₹1,353.50, while the 52-week low is ₹622.00. Currently trading at ₹1,044.70, the stock is 67.96% above its 52-week low and 22.81% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy INNOVA CAPTAB stock at the current price?

Whether to buy INNOVA CAPTAB stock at ₹1,044.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.26 and P/B ratio of 5.53. Today's performance shows a loss of 0.61%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of INNOVA CAPTAB and when is the next dividend?

INNOVA CAPTAB offers a dividend yield of 0.38%, which means for every ₹100 invested at the current price of ₹1,044.70, you can expect to receive approximately ₹0.38 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of INNOVA CAPTAB?

INNOVA CAPTAB's key financial metrics include: P/E Ratio: 38.26, P/B Ratio: 5.53, ROE: 12.92%, ROCE: 10.77%, Dividend Yield: 0.38%, EPS: ₹26.91, Book Value: ₹190.62, and Debt-to-Equity: 0.32. The company's market cap stands at ₹5,980.01 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is INNOVA CAPTAB stock performing today in the market?

INNOVA CAPTAB stock opened at ₹1,049.40 and is currently trading at ₹1,044.70, showing a decline of ₹6.40 (0.61%). The intraday high is ₹1,051.90 and low is ₹1,044.70. The trading volume stands at 24 shares, indicating moderate market participation today.

08What is the P/E ratio of INNOVA CAPTAB and what does it indicate?

INNOVA CAPTAB has a Price-to-Earnings (P/E) ratio of 38.26, which means investors are willing to pay 38.26 for every ₹1 of earnings. With an EPS of ₹26.91, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about INNOVA CAPTAB (INNOVACAP) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.